Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine.

Fredsøe J, Rasmussen AKI, Laursen EB, Cai Y, Howard KA, Pedersen BG, Borre M, Mouritzen P, Òrntoft T, Sørensen KD.

Clin Chem. 2019 Feb 6. pii: clinchem.2018.296681. doi: 10.1373/clinchem.2018.296681. [Epub ahead of print]

PMID:
30728149
2.

A new class of recombinant human albumin with multiple surface thiols exhibit stable conjugation, and enhanced FcRn binding and blood circulation.

Schelde KK, Nicholls K, Dagnæs-Hansen F, Bunting K, Rawsthorne H, Andersen B, Finnis CJA, Williamson M, Cameron J, Howard KA.

J Biol Chem. 2019 Jan 2. pii: jbc.RA118.005870. doi: 10.1074/jbc.RA118.005870. [Epub ahead of print]

3.

Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis.

Garcia JP, Stein J, Cai Y, Riemers F, Wexselblatt E, Wengel J, Tryfonidou M, Yayon A, Howard KA, Creemers LB.

J Control Release. 2019 Jan 28;294:247-258. doi: 10.1016/j.jconrel.2018.12.030. Epub 2018 Dec 18.

PMID:
30572032
4.

Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.

Larsen MT, Rawsthorne H, Schelde KK, Dagnæs-Hansen F, Cameron J, Howard KA.

J Control Release. 2018 Oct 10;287:132-141. doi: 10.1016/j.jconrel.2018.07.023. Epub 2018 Aug 29.

PMID:
30016735
5.

Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity.

Cai Y, Makarova AM, Wengel J, Howard KA.

J Gene Med. 2018 Jul;20(7-8):e3025. doi: 10.1002/jgm.3025. Epub 2018 Jun 25.

PMID:
29800498
6.

Can a brief biologically-based psychoeducational intervention reduce stigma and increase help-seeking intentions for depression in young people? A randomised controlled trial.

Howard KA, Griffiths KM, McKetin R, Ma J.

J Child Adolesc Ment Health. 2018 May;30(1):27-39. doi: 10.2989/17280583.2018.1467323. Epub 2018 May 15.

PMID:
29764293
7.

Targeting Biological Barriers: Turning a Wall into a Therapeutic Springboard.

Moghimi SM, Howard KA.

Mol Ther. 2018 Apr 4;26(4):933-934. doi: 10.1016/j.ymthe.2018.03.008. Epub 2018 Mar 21. No abstract available.

PMID:
29571965
8.

An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.

Kuhlmann M, Hamming JBR, Voldum A, Tsakiridou G, Larsen MT, Schmøkel JS, Sohn E, Bienk K, Schaffert D, Sørensen ES, Wengel J, Dupont DM, Howard KA.

Mol Ther Nucleic Acids. 2017 Dec 15;9:284-293. doi: 10.1016/j.omtn.2017.10.004. Epub 2017 Oct 7.

9.

The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria.

Christiansen SH, Murphy RA, Juul-Madsen K, Fredborg M, Hvam ML, Axelgaard E, Skovdal SM, Meyer RL, Sørensen UBS, Möller A, Nyengaard JR, Nørskov-Lauritsen N, Wang M, Gadjeva M, Howard KA, Davies JC, Petersen E, Vorup-Jensen T.

Sci Rep. 2017 Nov 15;7(1):15653. doi: 10.1038/s41598-017-15969-3.

10.

Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.

Hvam ML, Cai Y, Dagnæs-Hansen F, Nielsen JS, Wengel J, Kjems J, Howard KA.

Mol Ther. 2017 Jul 5;25(7):1710-1717. doi: 10.1016/j.ymthe.2017.05.009. Epub 2017 Jun 20.

11.

Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.

Schmidt EGW, Hvam ML, Antunes F, Cameron J, Viuff D, Andersen B, Kristensen NN, Howard KA.

J Biol Chem. 2017 Aug 11;292(32):13312-13322. doi: 10.1074/jbc.M117.794248. Epub 2017 Jun 21.

12.

Albumin-based drug delivery using cysteine 34 chemical conjugates - important considerations and requirements.

Caspersen MB, Kuhlmann M, Nicholls K, Saxton MJ, Andersen B, Bunting K, Cameron J, Howard KA.

Ther Deliv. 2017 Jul;8(7):511-519. doi: 10.4155/tde-2017-0038. Epub 2017 May 30.

PMID:
28555530
13.

Hyaluronic Acid Molecular Weight-Dependent Modulation of Mucin Nanostructure for Potential Mucosal Therapeutic Applications.

Hansen IM, Ebbesen MF, Kaspersen L, Thomsen T, Bienk K, Cai Y, Malle BM, Howard KA.

Mol Pharm. 2017 Jul 3;14(7):2359-2367. doi: 10.1021/acs.molpharmaceut.7b00236. Epub 2017 May 26.

PMID:
28499338
14.

High Frequency of Neuroimaging Abnormalities Among Pediatric Patients With Sepsis Who Undergo Neuroimaging.

Sandquist MK, Clee MS, Patel SK, Howard KA, Yunger T, Nagaraj UD, Jones BV, Fei L, Vadivelu S, Wong HR.

Pediatr Crit Care Med. 2017 Jul;18(7):607-613. doi: 10.1097/PCC.0000000000001173.

15.

Pellet-free isolation of human and bovine milk extracellular vesicles by size-exclusion chromatography.

Blans K, Hansen MS, Sørensen LV, Hvam ML, Howard KA, Möller A, Wiking L, Larsen LB, Rasmussen JT.

J Extracell Vesicles. 2017 Mar 15;6(1):1294340. doi: 10.1080/20013078.2017.1294340. eCollection 2017.

16.

Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding.

Schmøkel J, Voldum A, Tsakiridou G, Kuhlmann M, Cameron J, Sørensen ES, Wengel J, Howard KA.

Nanotechnology. 2017 May 19;28(20):204004. doi: 10.1088/1361-6528/aa6a9b. Epub 2017 Mar 31.

PMID:
28362634
17.

Using Technology to Enhance Discharge Teaching and Improve Coping for Patients After Stroke.

Schneider MA, Howard KA.

J Neurosci Nurs. 2017 Jun;49(3):152-156. doi: 10.1097/JNN.0000000000000275.

PMID:
28346312
18.

A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis.

Cai Y, López-Ruiz E, Wengel J, Creemers LB, Howard KA.

J Control Release. 2017 May 10;253:153-159. doi: 10.1016/j.jconrel.2017.03.004. Epub 2017 Mar 6.

PMID:
28274742
19.

Stress and Depression among Veterinary Medical Students.

Killinger SL, Flanagan S, Castine E, Howard KA.

J Vet Med Educ. Spring 2017;44(1):3-8. doi: 10.3138/jvme.0116-018R1.

PMID:
28206849
20.

Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response.

Johnson KM, Devine JM, Ho KF, Howard KA, Saretsky TL, Jamieson CA.

J Clin Psychiatry. 2016 Dec;77(12):1681-1686. doi: 10.4088/JCP.15m10253.

PMID:
28086004
21.

The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage.

Christiansen SH, Zhang X, Juul-Madsen K, Hvam ML, Vad BS, Behrens MA, Thygesen IL, Jalilian B, Pedersen JS, Howard KA, Otzen DE, Vorup-Jensen T.

Biochim Biophys Acta Biomembr. 2017 Mar;1859(3):425-437. doi: 10.1016/j.bbamem.2017.01.001. Epub 2017 Jan 5.

22.

Multimodal Imaging-Guided Antitumor Photothermal Therapy and Drug Delivery Using Bismuth Selenide Spherical Sponge.

Li Z, Liu J, Hu Y, Howard KA, Li Z, Fan X, Chang M, Sun Y, Besenbacher F, Chen C, Yu M.

ACS Nano. 2016 Oct 4. [Epub ahead of print]

PMID:
27689234
23.

Highly porous PEGylated Bi2S3 nano-urchins as a versatile platform for in vivo triple-modal imaging, photothermal therapy and drug delivery.

Li Z, Hu Y, Chang M, Howard KA, Fan X, Sun Y, Besenbacher F, Yu M.

Nanoscale. 2016 Sep 21;8(35):16005-16. doi: 10.1039/c6nr03398a. Epub 2016 Aug 22.

PMID:
27545304
24.

An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing.

Bienk K, Hvam ML, Pakula MM, Dagnæs-Hansen F, Wengel J, Malle BM, Kragh-Hansen U, Cameron J, Bukrinski JT, Howard KA.

J Control Release. 2016 Jun 28;232:143-51. doi: 10.1016/j.jconrel.2016.04.013. Epub 2016 Apr 12.

PMID:
27084489
25.

Albumin-based drug delivery: harnessing nature to cure disease.

Larsen MT, Kuhlmann M, Hvam ML, Howard KA.

Mol Cell Ther. 2016 Feb 27;4:3. doi: 10.1186/s40591-016-0048-8. eCollection 2016. Review.

26.

Hypokalaemia and drinking green tea: a literature review and report of 2 cases.

Chong SJ, Howard KA, Knox C.

BMJ Case Rep. 2016 Feb 16;2016. pii: bcr2016214425. doi: 10.1136/bcr-2016-214425.

27.

Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness.

Whitehead B, Wu L, Hvam ML, Aslan H, Dong M, Dyrskjøt L, Ostenfeld MS, Moghimi SM, Howard KA.

J Extracell Vesicles. 2015 Dec 28;4:29685. doi: 10.3402/jev.v4.29685. eCollection 2015.

28.

Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs.

Viuff D, Antunes F, Evans L, Cameron J, Dyrnesli H, Thue Ravn B, Stougaard M, Thiam K, Andersen B, Kjærulff S, Howard KA.

J Control Release. 2016 Feb 10;223:22-30. doi: 10.1016/j.jconrel.2015.12.019. Epub 2015 Dec 14.

PMID:
26699424
29.

Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours.

Martirosyan A, Olesen MJ, Fenton RA, Kjems J, Howard KA.

Nanoscale. 2016 Jul 7;8(25):12599-607. doi: 10.1039/c5nr07206a. Epub 2015 Dec 22.

PMID:
26694897
30.

Multifunctional Bismuth Selenide Nanocomposites for Antitumor Thermo-Chemotherapy and Imaging.

Li Z, Hu Y, Howard KA, Jiang T, Fan X, Miao Z, Sun Y, Besenbacher F, Yu M.

ACS Nano. 2016 Jan 26;10(1):984-97. doi: 10.1021/acsnano.5b06259. Epub 2015 Dec 16.

PMID:
26655250
31.

Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.

Petersen SS, Kläning E, Ebbesen MF, Andersen B, Cameron J, Sørensen ES, Howard KA.

Mol Pharm. 2016 Feb 1;13(2):677-82. doi: 10.1021/acs.molpharmaceut.5b00605. Epub 2015 Dec 29.

PMID:
26654692
32.

Home Improvement in HIV Primary Care: Investigating the Patient-Centered Medical Home Model for People Living with HIV/AIDS.

Friedman EG, Crowley M, Howard KA, Pavel MP.

Popul Health Manag. 2015 Oct;18(5):323-9. doi: 10.1089/pop.2014.0150. Epub 2015 Apr 13.

PMID:
25867483
33.

Albumin: the next-generation delivery technology.

Howard KA.

Ther Deliv. 2015 Mar;6(3):265-8. doi: 10.4155/tde.14.124. No abstract available.

34.

The application of RNAi-based treatments for inflammatory bowel disease.

Olesen MT, Ballarín-González B, Howard KA.

Drug Deliv Transl Res. 2014 Feb;4(1):4-18. doi: 10.1007/s13346-013-0156-9.

PMID:
25786614
35.

RNA interference-based therapeutics and diagnostics.

Peer D, Howard KA.

Drug Deliv Transl Res. 2014 Feb;4(1):1-2. doi: 10.1007/s13346-013-0182-7. No abstract available.

PMID:
25786612
36.

Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.

Martirosyan A, Olesen MJ, Howard KA.

Adv Genet. 2014;88:325-52. doi: 10.1016/B978-0-12-800148-6.00011-0. Review.

PMID:
25409611
37.

Comparative analysis of discrete exosome fractions obtained by differential centrifugation.

Jeppesen DK, Hvam ML, Primdahl-Bengtson B, Boysen AT, Whitehead B, Dyrskjøt L, Orntoft TF, Howard KA, Ostenfeld MS.

J Extracell Vesicles. 2014 Nov 6;3:25011. doi: 10.3402/jev.v3.25011. eCollection 2014.

38.

Tunable CD44-specific cellular retargeting with hyaluronic acid nanoshells.

Ebbesen MF, Olesen MT, Gjelstrup MC, Pakula MM, Larsen EK, Hansen IM, Hansen PL, Mollenhauer J, Malle BM, Howard KA.

Pharm Res. 2015 Apr;32(4):1462-74. doi: 10.1007/s11095-014-1552-7. Epub 2014 Nov 1.

PMID:
25361867
39.

Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties.

Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B, Hendrix A, Lamy P, Dagnaes-Hansen F, Rasmussen MH, Bui KH, Fristrup N, Christensen EI, Nordentoft I, Morth JP, Jensen JB, Pedersen JS, Beck M, Theodorescu D, Borre M, Howard KA, Dyrskjøt L, Ørntoft TF.

Cancer Res. 2014 Oct 15;74(20):5758-71. doi: 10.1158/0008-5472.CAN-13-3512. Epub 2014 Sep 26.

40.

Mucus barrier-triggered disassembly of siRNA nanocarriers.

Thomsen TB, Li L, Howard KA.

Nanoscale. 2014 Nov 7;6(21):12547-54. doi: 10.1039/c4nr01584c.

PMID:
25179224
41.

Spatial mapping and quantification of soft and hard protein coronas at silver nanocubes.

Miclăuş T, Bochenkov VE, Ogaki R, Howard KA, Sutherland DS.

Nano Lett. 2014;14(4):2086-93. doi: 10.1021/nl500277c. Epub 2014 Mar 19.

PMID:
24617413
42.

Ultraporous interweaving electrospun microfibers from PCL-PEO binary blends and their inflammatory responses.

Li YF, Rubert M, Aslan H, Yu Y, Howard KA, Dong M, Besenbacher F, Chen M.

Nanoscale. 2014 Mar 21;6(6):3392-402. doi: 10.1039/c3nr06197c. Epub 2014 Feb 14.

PMID:
24531205
43.

Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.

Jeppesen DK, Nawrocki A, Jensen SG, Thorsen K, Whitehead B, Howard KA, Dyrskjøt L, Ørntoft TF, Larsen MR, Ostenfeld MS.

Proteomics. 2014 Mar;14(6):699-712. doi: 10.1002/pmic.201300452. Epub 2014 Feb 16. Erratum in: Proteomics. 2014 Nov;14(21-22):2628-9.

PMID:
24376083
44.

Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis.

Ebbesen MF, Bienk K, Deleuran BW, Howard KA.

Mol Cell Ther. 2014 Sep 11;2:29. doi: 10.1186/2052-8426-2-29. eCollection 2014.

45.

Reliability, validity, and interpretation of the dependence scale in mild to moderately severe Alzheimer's disease.

Lenderking WR, Wyrwich KW, Stolar M, Howard KA, Leibman C, Buchanan J, Lacey L, Kopp Z, Stern Y.

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):738-49. doi: 10.1177/1533317513504609.

PMID:
24363071
46.

Cell type and transfection reagent-dependent effects on viability, cell content, cell cycle and inflammation of RNAi in human primary mesenchymal cells.

Yang HY, Vonk LA, Licht R, van Boxtel AM, Bekkers JE, Kragten AH, Hein S, Varghese OP, Howard KA, Öner FC, Dhert WJ, Creemers LB.

Eur J Pharm Sci. 2014 Mar 12;53:35-44. doi: 10.1016/j.ejps.2013.12.006. Epub 2013 Dec 15.

PMID:
24345796
47.

Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease.

Wilcox TK, Chen WH, Howard KA, Wiklund I, Brooks J, Watkins ML, Cates CE, Tabberer MM, Crim C.

Health Qual Life Outcomes. 2013 Nov 14;11:196. doi: 10.1186/1477-7525-11-196.

48.

Polycation-based nanoparticles for RNAi-mediated cancer treatment.

Ballarín-González B, Ebbesen MF, Howard KA.

Cancer Lett. 2014 Sep 28;352(1):66-80. doi: 10.1016/j.canlet.2013.09.023. Epub 2013 Oct 15. Review.

PMID:
24139965
49.

Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery.

Howard KA, Peer D.

Nanomedicine (Lond). 2013 Jul;8(7):1031-3. doi: 10.2217/nnm.13.95. No abstract available.

50.

Surface analysis of PEGylated nano-shields on nanoparticles installed by hydrophobic anchors.

Ebbesen MF, Whitehead B, Ballarin-Gonzalez B, Kingshott P, Howard KA.

Pharm Res. 2013 Jul;30(7):1758-67. doi: 10.1007/s11095-013-1018-3. Epub 2013 Apr 12.

PMID:
23579480

Supplemental Content

Loading ...
Support Center